Not Yet RecruitingACTRN12618001107213
Official study titleKeep it Real: A web-based program for psychotic-like experiences and cannabis use
A Randomised Controlled Trial, Testing the Efficacy of the “Keep it Real” Website
This study isn't recruiting yet.
In AustraliaSchizophreniaInterventional studyAges 16–25
- Countries
- Australia
- Sponsor
- University of Queensland
RecruitingEUCTR 2017-001170-42
This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.
Multiple locations, including GdańskSchizophreniaHistorical research record
- Countries
- Poland
- Sponsor
- SyneuRx International (Taiwan) Corp
RecruitingEUCTR 2022-000054-28
This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.
Multiple locations, including AugsburgSchizophreniaHistorical research record
- Countries
- Germany
- Sponsor
- Klinikum der Universität München
RecruitingEUCTR 2022-001582-12
This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.
Multiple locations, including BarcelonaSchizophreniaHistorical research record
- Countries
- Spain
- Sponsor
- Consorcio Centro de Investigacion Biomedica en Red (CIBER)
RecruitingNCT04478838
Official study title"Re-examining Maintenance Antipsychotic Treatment in Schizophrenia: "Extended" Antipsychotic Dosing"
In TorontoSchizophreniaMedication studyAges 18+
- Countries
- Canada
- Sponsor
- Centre for Addiction and Mental Health (Hospital / academic medical center)
RecruitingNCT07369154
What is this study about?This study evaluates the safety of LB-102 for people with schizophrenia.
Multiple locations, including ChandlerSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- LB Pharmaceuticals Inc.
RecruitingNCT07615426
What is this study about?This study evaluates the safety of Aticaprant for people with schizophrenia.
Multiple locations, including Garden GroveSchizophreniaMedication studyAges 18–60
- Countries
- United States
- Sponsor
- Janssen Research & Development, LLC
RecruitingNCT07221877
Official study titleA 12-month Open-label, Phase 4 Multicenter Safety Study to Evaluate the Effect of KarXT on Voiding Dynamics and Urological Safety
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Bristol-Myers Squibb (Pharmaceutical company)
RecruitingNCT03094429
What is this study about?This study evaluates the safety and effectiveness of NaBen® for people with schizophrenia.
In PasadenaSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- SyneuRx International (Taiwan) Corp
RecruitingNCT02640911
Official study titleAn Observational Study on Atypical Antipsychotics Long-term Treatment Patients With Schizophrenia
In ShanghaiSchizophreniaObservational studyAges 18+
- Countries
- China
- Sponsor
- Shanghai Mental Health Center
RecruitingNCT04113993
Official study titleBazedoxifene - A New Selective Estrogen Receptor Modulator Treatment for Women With Schizophrenia: a Double-blind, Randomized, Placebo Controlled Trial
In MelbourneSchizophreniaMedication studyAges 18–65
- Countries
- Australia
- Sponsor
- The Alfred
RecruitingNCT06817980
In StrasbourgPersonality disorders, SchizophreniaBehavioural studyAges 18–60
- Countries
- France
- Sponsor
- University Hospital, Strasbourg, France